

ASX Announcement

12 April 2021

AnteoTech Rapid Test Platform and COVID-19 Test Receive CE Mark Registration



Highlights

- ❖ Reader and test platform trademarked – EuGeni
- ❖ EuGeni product launch event and webcast end April 2021
- ❖ CE Mark registration achieved for EuGeni Rapid Test Platform and COVID-19 Antigen Rapid Test (ART) based on proprietary AnteoBind Activated Europium technology
- ❖ EuGeni Rapid Test Platform is expected to create a new revenue stream and a leverage opportunity to develop further rapid tests, maximising reader capability

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to advise that it has received Conformité Européenne (CE) Mark registration for its EuGeni Reader and the *in vitro* rapid diagnostic test for the detection of SARS-CoV-2 nucleocapsid antigen, the COVID-19 ART.

The CE Mark registration confirms that the EuGeni Reader and the COVID-19 ART conform with health and safety protection standards for products sold within the European Economic Area (EE) and the United Kingdom. Further, it supports the sale of AnteoTech's EuGeni Reader and the COVID-19 ART which uses the unique AnteoBind Activated Europium technology, to deliver a high performing and high sensitivity test.

With CE Mark achieved, AnteoTech is now a recognised lateral flow immunoassay rapid test manufacturer. The EuGeni Rapid Test Platform provides the basis of an entirely new potential revenue stream for the Company. This revenue stream is expected to grow with the addition of not only the proposed COVID-19 suite of tests but also the development of a range of new diagnostic solutions in the areas of infectious, bacterial and viral conditions.

AnteoTech has a commercialisation strategy in place to drive initial sales of EuGeni readers into key markets via the COVID-19 ART and the COVID-19/Flu A/Flu B Multiplex tests. The EuGeni reader base established from this program will be leveraged with the introduction of new tests that require rapid diagnostics to deliver critical clinical decision support and have the potential for a high level of market demand.

The first of these will be a quantitative test for Sepsis, the body's extreme and life-threatening response to infection. The delivery of effective lifesaving treatment for Sepsis is time critical, it is difficult to diagnose Sepsis promptly and it is often missed when it could be more effectively treated, resulting in a very high global mortality rate, significantly beyond that of COVID-19 today.¹

Following initial introductions and discussions with distributors over the past weeks, the receipt of CE Mark will now allow AnteoTech to formalise marketing and distribution discussions which are expected to enable AnteoTech to capture a share of the growing and evolving antigen rapid testing market in Europe and the UK.

AnteoTech CEO Derek Thomson commented: "We are delighted to have achieved this significant milestone in our strategy to become a legal manufacturer of rapid tests. It is a transformative moment, the culmination of twelve months of intensive effort."

"The EuGeni Platform provides a strong foundation for us to grow a suite of qualitative and quantitative tests for the Point-of-Care market and I am excited by the immediate opportunity and the leverage opportunities that lie ahead of us."

"CE Mark for the COVID-19 ART provides us with an opportunity to capture some of the large and growing European antigen rapid test market. We believe we have a superior test with high sensitivity and specificity based on our unique AnteoBind technology. We will soon enhance this offering with a saliva use case and new COVID-19/Flu A/Flu B Multiplex test, which will give us a very strong competitive advantage over other products currently on the market."

"I'd like to commend the commitment, dedication and skills of the entire Life Science team at AnteoTech under the leadership of Dr. Charlie Huang. They are a very small team of talented people that have achieved outstanding results. From very humble beginnings, Charlie and his team have helped to accelerate our Company beyond what we originally envisaged in the time frame of this development. I would also like to thank the Queensland Government for their contribution through the Essential Goods and Supply Chain Program, to the commercialisation of our test and platform."



¹ World Health Organisation Global Report on Sepsis, September 2020

EuGeni Product Launch Event

An official product launch for the EuGeni Reader and COVID-19 ART will be held in Brisbane, towards the end of April. An invitation to register for the launch webcast will be shared in the coming weeks.

About EuGeni COVID-19 Antigen Rapid Test

The EuGeni COVID-19 Antigen Rapid Test is a single use, disposable immunochromatographic rapid diagnostic test intended to be used by healthcare professionals for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal specimens collected from individuals who are suspected of COVID-19 infection. The results from this in vitro diagnostic test identifies the presence or absence of the SARS-CoV-2 antigen as an aid in the diagnosis of COVID-19 infection. The EuGeni COVID-19 ART has an overall sensitivity of 97.3% and specificity of 99.6%.²

This announcement has been authorised for release by the Board.

For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit www.anteotech.com

